Lakefront Biotherapeutics NV (LKFT) AI Stock Analysis

Lakefront Biotherapeutics NV, formerly known as Galapagos NV until May 2026, is a Mechelen, Belgium-based biotechnology firm incorporated in 1999. The company focuses on developing oncology and immunology medicines primarily in the United States and Europe. Its clinical-stage pipeline includes GLPG3667, in Phase 2 for dermatomyositis and systemic lupus erythematosus; GLPG5101, a point-of-care manufactured CD19 CAR-T candidate in Phase 1/2 for relapsed or refractory non-Hodgkin lymphoma; and GLPG5301, a point-of-care BCMA CAR-T candidate in Phase 1/2 for relapsed or refractory multiple myeloma. The company also maintains collaboration agreements with Gilead Sciences, Inc.

From FY2021 to FY2025, revenue grew at a four-year compound annual growth rate of 47.6%, rising from $234.4M in FY2021 to $1.11B in FY2025. Annual net income shifted from a net loss of $103.2M in FY2021 to net income of $320.9M in FY2025, yielding an EPS of $12.13 and an operating margin of 45.1%. R&D expense was $459.4M in FY2025. In the trailing twelve months ending June 30, 2026, revenue stood at $990.6M with a profit margin of 60.2% and an operating margin of -359.3%. Quarterly revenue fell 81.5% year-over-year in the quarter ended June 30, 2026.

As of June 30, 2026, Lakefront Biotherapeutics held $2.24B in cash and short-term investments compared to $6.4M in total debt, yielding net cash of $2.23B. Shareholders' equity was $3.25B on total assets of $3.35B, resulting in a current ratio of 32.82 and a debt-to-equity ratio of 0.00. Cash flow remained negative in FY2025, with operating cash flow of -$257.5M and free cash flow of -$271.3M. In FY2025, capital expenditures totaled $13.9M, while the share count increased 7.2% over five years.

At a share price of $29.90 on October 16, 2026, LKFT had a market capitalization of $1.96B and an enterprise value of -$581.2M. LKFT trades at a trailing price-to-earnings ratio of 2.8x, compared to 24.6x for the median of its US-listed Healthcare peers. Its forward P/E is 344.8x compared to the peer median of 17.3x, and its price-to-sales ratio is 2.0x versus the peer median of 4.1x. Over the past year, LKFT shares returned -12.3%, trailing the S&P 500 (SPY) return of 16.8%, and returned -44.1% over five years versus 83.0% for the S&P 500.

Wall Street coverage includes 6 ratings: 1 Strong Buy, 1 Buy, 3 Holds, 0 Sells, and 1 Strong Sell. The mean price target is $30.29, representing an implied upside of 1.3% over the last close of $29.90. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.71 on revenue of $117.2M. For the following fiscal year, 2 analysts project an EPS of -$1.06 on revenue of $84.6M, representing a revenue decline of 27.8%. The company beat EPS estimates in all of the last 4 quarters.

This page is an AI-written research summary of Lakefront Biotherapeutics NV (LKFT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LKFT income statement, LKFT balance sheet, LKFT key metrics, LKFT analyst forecast, LKFT chart. See the LKFT stock overview for the latest quote and news.